cefuroxime

Brand: Zinacef, Ceftin

Prototype Drug
Drug Class: second-generation cephalosporin
Drug Family: antibiotic
Subclass: oral and parenteral second-generation cephalosporin
Organ Systems: infectious-disease

Mechanism of Action

Inhibits cell wall synthesis by binding PBPs; offers enhanced gram-negative spectrum over first-generation cephalosporins including H. influenzae and M. catarrhalis, while maintaining gram-positive activity.

penicillin-binding proteins (PBPs)

Indications

  • community-acquired pneumonia
  • sinusitis
  • otitis media
  • skin and soft tissue infections
  • UTI
  • Lyme disease (early)
  • surgical prophylaxis

Contraindications

  • cephalosporin hypersensitivity

Adverse Effects

Common

  • diarrhea
  • nausea
  • metallic taste (oral)

Serious

  • anaphylaxis
  • C. difficile colitis
  • hemolytic anemia

Pharmacokinetics (ADME)

Absorption oral axetil prodrug: 37–52% bioavailability, increased with food; IV/IM: complete absorption
Distribution widely distributed; poor CSF penetration (unless inflamed meninges)
Metabolism axetil prodrug hydrolyzed to active cefuroxime in intestinal mucosa
Excretion renal (unchanged)
Half-life 1–2 hours
Onset rapid
Peak 2–3 hours (oral), 30 min (IV/IM)
Duration 8–12 hours
Protein Binding 33–50%
Vd moderate

Drug Interactions

Drug / Agent Mechanism Severity
probenecid reduces renal tubular secretion, increases cefuroxime levels minor
antacids/H2 blockers reduced oral absorption of cefuroxime axetil prodrug moderate

Nursing Considerations

  1. Administer oral cefuroxime axetil with food to improve bioavailability and reduce GI upset.
  2. IV infusion: administer over 15–60 minutes; monitor for phlebitis at infusion site.
  3. Reduce dose in severe renal impairment (CrCl <20 mL/min).
  4. For early Lyme disease, 500 mg twice daily for 14–21 days is the standard regimen; counsel patient to complete the full course.

Clinical Pearls

  • Cefuroxime is one of the few second-generation cephalosporins available in both oral and IV formulations, allowing convenient oral step-down therapy.
  • Its prodrug formulation (cefuroxime axetil) is activated by intestinal esterases; reduced gastric pH from antacids or H2 blockers can impair this activation.

Safety Profile

Pregnancy generally-safe
Lactation use-with-caution
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required